NOV 09, 2017 10:30 AM PST
Fast Phenotypic Antibiotic Susceptibility Testing of Positive Blood Cultures
Presented at the Clinical Diagnostics & Research 2017 Virtual Event
SPONSORED BY: Accelerate Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 1 24

Speakers:
  • Professor of Pathology and Laboratory Medicine, Scientific Director and Microbiology, Cedars-Sinai Medical Center
    Biography
      I am a clinical microbiologist and currently the scientific director of microbiology at Cedars- Sinai Medical Center in Los Angeles, CA. I love to teach, and during my thirty years in microbiology I have taught enumerable pathology residents, infectious disease fellows, pharmacists, infection control nurses, and clinical laboratory scientists. I have reviewed hundreds of pathology residents for their board examination at the Osler Institute Pathology Review Course. It has been my goal to spread the science and art of microbiology to whoever would look and listen. I love to teach microbiology!

    Abstract:

    The role of the microbiology laboratory in the processing of positive patient blood cultures has become more complicated with the increasing demand for rapid information to assist in the management of sepsis.  Many laboratories have turned to using molecular systems that report identification and resistant marker results that supply actionable information but no susceptibility data.  These systems have proven over time to be useful with the management of Gram positive bloodstream infections but vary in the ability to properly guide therapy choices for Gram negative bacteremia.   In our institution, phenotypic antimicrobial susceptibility results are often necessary for optimization of therapy. This is particularly true due to emerging resistance mechanisms in Gram negative bacilli, such as AmpC and porin alterations.  The Accelerate Pheno™ system is a truly unique and divergent technology that has the potential to produce final susceptibility results directly from a positive blood culture within 7 hours.  This is a reduction in time to results from conventional susceptibility methods of 2-3 days.   The Accelerate Diagnostics system was FDA cleared in February of 2017.  Clinical trial and scientific presentations have shown the identification and MIC susceptibility results to be reliable and can be used to improve patient care.  Rapid final MIC results provide invaluable information to a stewardship program to rapidly optimize the therapy of sepsis.


    Show Resources
    Loading Comments...